Trial Profile
A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety and tolerability of VS-01 on top of standard of care, compared to standard of care alone, in adult patients with acute-on-chronic liver failure (ACLF) grades 1 and 2 and ascites
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Citric acid (Primary)
- Indications Ascites; Hepatic encephalopathy; Liver cirrhosis; Liver failure
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms UNVEIL; UNVEIL-IT
- Sponsors Versantis
- 04 Apr 2024 According to a Genfit media release, Topline interim data expected in 2H24
- 06 Feb 2024 Maximum age limit for inclusion criteria is increased from 64 to 69 years, thus including elderly patients as well.
- 16 Nov 2023 According to Genfit media release, interim data readout targeted for the end of 2Q24